Morral N, O'Neal W, Rice K, Leland M, Kaplan J, Piedra P A, Zhou H, Parks R J, Velji R, Aguilar-Córdova E, Wadsworth S, Graham F L, Kochanek S, Carey K D, Beaudet A L
Department of Molecular Genetics, Baylor College of Medicine, Houston, TX 77030, USA.
Proc Natl Acad Sci U S A. 1999 Oct 26;96(22):12816-21. doi: 10.1073/pnas.96.22.12816.
The efficiency of first-generation adenoviral vectors as gene delivery tools is often limited by the short duration of transgene expression, which can be related to immune responses and to toxic effects of viral proteins. In addition, readministration is usually ineffective unless the animals are immunocompromised or a different adenovirus serotype is used. Recently, adenoviral vectors devoid of all viral coding sequences (helper-dependent or gutless vectors) have been developed to avoid expression of viral proteins. In mice, liver-directed gene transfer with AdSTK109, a helper-dependent adenoviral (Ad) vector containing the human alpha(1)-antitrypsin (hAAT) gene, resulted in sustained expression for longer than 10 months with negligible toxicity to the liver. In the present report, we have examined the duration of expression of AdSTK109 in the liver of baboons and compared it to first-generation vectors expressing hAAT. Transgene expression was limited to approximately 3-5 months with the first-generation vectors. In contrast, administration of AdSTK109 resulted in transgene expression for longer than a year in two of three baboons. We have also investigated the feasibility of circumventing the humoral response to the virus by sequential administration of vectors of different serotypes. We found that the ineffectiveness of readministration due to the humoral response to an Ad5 first-generation vector was overcome by use of an Ad2-based vector expressing hAAT. These data suggest that long-term expression of transgenes should be possible by combining the reduced immunogenicity and toxicity of helper-dependent vectors with sequential delivery of vectors of different serotypes.
第一代腺病毒载体作为基因传递工具的效率常常受到转基因表达持续时间短的限制,这可能与免疫反应以及病毒蛋白的毒性作用有关。此外,除非动物免疫功能低下或使用不同的腺病毒血清型,再次给药通常无效。最近,为了避免病毒蛋白的表达,已开发出不含所有病毒编码序列的腺病毒载体(辅助依赖型或无基因组载体)。在小鼠中,用AdSTK109(一种含有人类α1-抗胰蛋白酶(hAAT)基因的辅助依赖型腺病毒(Ad)载体)进行肝脏定向基因转移,导致持续表达超过10个月,对肝脏的毒性可忽略不计。在本报告中,我们研究了AdSTK109在狒狒肝脏中的表达持续时间,并将其与表达hAAT的第一代载体进行了比较。第一代载体的转基因表达限于约3至5个月。相比之下,给予AdSTK109后,三只狒狒中有两只的转基因表达持续了一年以上。我们还研究了通过依次给予不同血清型的载体来规避对病毒的体液反应的可行性。我们发现,使用表达hAAT的基于Ad2的载体克服了因对Ad5第一代载体的体液反应而导致的再次给药无效性。这些数据表明,通过将辅助依赖型载体降低的免疫原性和毒性与依次递送不同血清型的载体相结合,转基因的长期表达应该是可能的。